GENETIC TECHNOLOGIES LIMITED — Capital/Financing Update 2024

Sep 10, 2024

ASX Market Announcement

==> picture [78 x 49] intentionally omitted <==

Entitlement Offer Results and Closing

Melbourne, Australia, 11 September, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the Entitlement Offer closed on Monday, 9 September 2024 (Closing Dated), raising $324,648 from Eligible Shareholders.

The Company received applications from Eligible Shareholders for 8,116,205 shares at an issue price of $0.04 with one free attaching option, raising $324,648 (before costs). This includes applications from Eligible Shareholders for additional shares under the Top-Up Offer. This is a strong level of participation, considering that more than 70% of the Company’s shares are held by US based shareholders who are not eligible to participate in the Entitlement Offer.

Accordingly, the total shortfall under the Entitlement Offer is 88,828,626 New Shares at an issue price of $0.04 with one free attaching option, which equates to a shortfall amount of up to $3,553,145. In addition to the pre-commitments of $500,000 from Directors and others, the Company has also received Shortfall Commitments after the close of the retail offer under the Entitlement Offer. To date, the total approximate value of the pre-commitments, shortfall commitments and the entitlement offer applications is approximately $1 million.

As noted in the Entitlement Offer Prospectus – all allotments under the Entitlement Offer are subject to raising the minimum of $2 million (including the Shortfall Commitments). Accordingly, the Company has extended the period under the Entitlement Offer Prospectus to receive Shortfall Commitments (as permitted under section 724 of the Corporations Act and the Entitlement Offer Prospectus) at a price not less than $0.04 per share together with one free attaching option.

No allotments will occur until the minimum of $2 million in applications is received; and the Company will provide a further update to the ASX market on the progress of the Shortfall Offer under the Entitlement Offer Prospectus.

The Company is now actively working with Brokers to place the shortfall with significant interest already received.

The Board thanks shareholders for their high participation rates and ongoing support.

The following table sets out a summary of the outcome of the Entitlement Offer:

Description	Number NewShares	Number NewOptions
Maximum numbers of shares and attachingoptions under the Entitlement Offer	96,944,831	96,944,831
Total applications received by the Companyfrom Eligible Shareholders	8,116,205	8,116,205
Remaining available shortfall	88,828,626	88,828,626

1

- END -

Authorised for release by the Board of Directors.

Enquiries

Peter Rubinstein Chairman E: investors@genetype.com

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

Forward Looking Statements

This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forwardlooking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

2